2022 World Conference on Lung Cancer (ePosters)-EP08.02-090. Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide

Pdf Summary

The study investigates the drug-drug interactions (DDIs) caused by the drug sotorasib (LUMYKRAS/LUMAKRAS) and the guidance requested by physicians worldwide to ensure safe and effective treatment with sotorasib in routine clinical practice. Polypharmacy, the use of multiple medications, is common in lung cancer patients, and DDIs can complicate optimal drug treatment. The study was conducted by researchers from the Department of Pharmacy and Radboud Institute for Health Sciences at Radboud University Medical Center in the Netherlands, the Department of Pharmacology and Therapeutics at the University of Liverpool in the United Kingdom, and the Department of Pulmonology at Radboud University Medical Center.<br /><br />Between July 2021 and February 2022, there were 747 queries regarding DDIs between sotorasib and 409 comedications. The most frequently requested combinations were sotorasib with direct-acting oral anticoagulants (DOACs) and acid reducing drugs (H2-antagonists, proton-pump inhibitors, and antacids). The coadministration of sotorasib with these drugs often requires intervention. The results highlight the need for practical guidance for managing DDIs with sotorasib. Prospective studies on DDIs between sotorasib and DOACs are necessary.<br /><br />The study analyzed the requested drug combinations using the Cancer Interaction Checker developed by Radboud University Medical Center and the University of Liverpool. The DDIs were graded based on their potential clinical significance. Approximately 48% of the DDIs required intervention.<br /><br />In conclusion, there is a clinical need for guidance on combining sotorasib with other medications to address relevant DDIs. The study emphasizes the importance of practical recommendations for handling DDIs with sotorasib, particularly with DOACs and acid-reducing drugs. The findings underscore the need for prospective DDI studies and support the development of guidance for physicians in managing DDIs with sotorasib.

Asset Subtitle

Leila-Sophie Otten

Meta Tag

Speaker Leila-Sophie Otten

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

drug-drug interactions

sotorasib

LUMYKRAS

LUMAKRAS

physicians

safe and effective treatment

polypharmacy

lung cancer patients

direct-acting oral anticoagulants

acid reducing drugs